[Feng Yu/Adobe Stock]
The GLP-1 drug market continues to boom lately thanks to highly effective new medications like Novo Nordisk’s Wegovy and continued demand for the drug class in diabetes. The runaway success of Wegovy and Ozempic (both formulations of semaglutide) has caused Novo Nordisk’s share price to skyrocket in 2023, briefly making the Danish pharmaceutical company the most valuable in Europe by market capitalization. Novo Nordisk’s growth has even exceeded Denmark’s entire economic output. Far-ranging GLP-1 landscape projectionsGiven the massive potential of the obesity drug market, with projections ranging from Goldman Sachs’ $44 billion to Barclays’ $100 billion by 2030, Big Pharmas such as Novo Nordisk and Lilly are engaging in billion-dollar acquisitions of smaller biotechs with promising obesity pipelines.
At present, Novo Nordisk is having troubling ke…